You are here:
06 May 2021 / news

Life Sciences Bit: Tightened Swiss regulatory requirements in relation to international pharmaceuticals trading

Swiss wholesale license holder must tighten their audit practices towards suppliers from countries outside of the EU.

Life Sciences Bit Tightened Swiss regulatory requirements in relation to international pharmaceuticals trading

Foreign pharmaceuticals trade from Switzerland

Entities active in Switzerland in international trading of pharmaceuticals are required to apply for and to maintain a Swiss wholesale license or a special Swiss foreign trade license with the competent supervisory authority Swissmedic. A license is required even if there is no physical flow of goods within the Swiss territory.

The rationale for the license requirement is to ensure that all pharmaceuticals distributed by entities active in Switzerland comply with the EU GDP regulations guaranteeing high standards even abroad.

Tightened regulatory requirements

Swissmedic reports in a press release of recent cases where Swiss entities distributed abroad pharmaceuticals that turned out to be counterfeits. These products were sourced from suppliers in countries that do not have regulations equivalent to the EU GDP standards.

Therefore, Swissmedic communicated that it expects Swiss license holders to tighten their audit practices in relation to suppliers of finished pharmaceuticals from non-EU countries.

In particular, Swissmedic reminds license holders that they must verify that their suppliers are fully compliant with all EU GDP requirements, meaning that in addition to a document review, the license holder must carry out an in-depth audit of the supplier. Moreover, the license holder must have detailed knowledge of the local regulations and be able to reconstruct the supply chain of finished pharmaceuticals through all steps up to the marketing authorization holder.

Detailed information on all Swiss regulatory requirements in relation to licenses can be found online (in English) in the Swiss Therapeutic Products Act, the Swiss Medicinal Products Licensing Ordinance and in the relevant technical interpretation by Swissmedic (“Legal requirements and mandatory due diligence by Swiss firms wishing to engage in foreign trade with medicinal products from Switzerland”).

Enforcement measures

Swissmedic also specifically announces that it will take all appropriate administrative and criminal measures against any violation of the law by non-compliant foreign trade license holders, including ordering recalls and withdrawing licenses if appropriate.

Need for action

We recommend reviewing if the internal policies and procedures comply with the tightened regulatory practice in relation to non-EU suppliers.

If you have any question on the subject or would you be interested in an introductory meeting contact Gilles Pitschen or click here for further details about our healthcare & life science legal services.


Written resolutions of the board of directors

Written resolutions of the board of directors

Valérie Schrämli has recently published a short article about written resolutions in the board of directors of Swiss companies read more
Swiss Special Purpose Acquisition Company – Frequently Asked Questions

Swiss Special Purpose Acquisition Company – FAQ

The number of IPOs in the US more than doubled in 2020 compared to 2019. read more
Legal 500 EMEA Rankings 2021

Loyens & Loeff Switzerland ranked in Legal 500 EMEA 2021

Congratulations to all our team members in different practice areas in Switzerland for the excellent Legal 500 EMEA 2021 rankings. read more